Abstract:Background: Obesity is a major threat to public health and traditional bariatric surgery continues to have low utilization. Endoscopic treatments for obesity have emerged that offer less risk, but questions remain regarding efficacy, durability, and safety. We compared the efficacy of endoscopic bariatric procedures as compared to other existing treatments. Methods: A literature search of Embase, Cochrane Central, and Pubmed was conducted from January 1, 2014 to December 7, 2021, including endoscopic bariatric therapies that were FDA or CE approved at the time of search to non-endoscopic treatments. Thirty-seven studies involving 15,639 patients were included. Primary outcomes included % total body weight loss (%TBWL), % excess body weight loss (%EBWL), and adverse events. Secondary outcomes included quality of life data and differences in hemoglobin A1C levels. Strength of clinical trial and observational data were graded according to the Cochrane methods. Results: Intragastric balloons achieved greater %TBWL with a range of 7.6-14.1% compared to 3.3-6.7% with lifestyle modification at 6 months, and 7.5-14.0% compared to 3.1-7.9%, respectively, at 12 months. When endoscopic sleeve gastroplasty (ESG) was compared to laparoscopic sleeve gastrectomy (LSG), ESG had less %TBWL at 4.7-14.4% compared to 18.8-26.5% after LSG at 6 months, and 4.5-18.6% as compared to 28.4-29.3%, respectively, at 12 months. For the AspireAssist, there was greater %TBWL with aspiration therapy compared to lifestyle modification at 12 months, 12.1-18.3% TBWL versus 3.5-5.9% TBWL, respectively. All endoscopic interventions had higher adverse events rates compared to lifestyle modification. Conclusion: This review is the first to evaluate various endoscopic bariatric therapies using only RCTs and observational studies for evaluation of weight loss compared with conservative management, lifestyle modification, and bariatric surgery. Endoscopic therapies result in greater weight loss compared to lifestyle modification, but not as much as bariatric surgery. Endoscopic therapies may be beneficial as an alternative to bariatric surgery.

Bariatrics and endoscopic therapies for the treatment of metabolic disease: Past, present, and future

Small intestine-targeted endoscopic bariatrics: current status and future perspectives.

Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks

Endoscopic Bariatric and Metabolic Therapies and Its Effect on MASLD: A Review of the Current Literature

Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis

Future Prospects of Metabolic and Bariatric Surgery: A Comprehensive Review

The Future of Endobariatrics: Bridging the Gap

Small Bowel Therapies for Metabolic Disease and Obesity

Update on Endoscopic Treatments for Obesity

From surgery to endoscopy: the evolution of the bariatric discipline

Endoscopic therapies for patients with obesity: a systematic review and meta-analysis

Novel Surgical Interventions for the Treatment of Obesity

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Novel Endoscopic Management of Obesity

Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery

Endoluminal Treatments for Obesity and Related Hypertension: Updates, Review, and Clinical Perspective

Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond

A commentary review on endoscopic sleeve gastroplasty: Indications, outcomes and future implications

Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms

American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity

New insights into the treatment of obesity.